Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH: Methylprednisolone or Equine Anti-Thymocyte Globulin for Pediatric Acute Liver Failure
NCT04862221Phase 2Active, not recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Feb 2022
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of methylprednisolone injection, antilymphocyte immunoglobulin (horse) in acute liver failure (ALF), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Feb 2022; status: active, not recruiting.
02
Drugs
methylprednisolone injectionantilymphocyte immunoglobulin (horse)
03
Conditions
acute liver failure (ALF)
Beyond the preview
Go deeper on NCT04862221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04862221.